Praxis Bioresearch said today it has won a $1.5 million Fast-Track Small Business Innovation Research (SBIR) grant from the NIH toward ongoing development of the company’s lead product candidate PRX-P4-003, a prodrug stimulant designed to significantly reduce the risk of abuse.

PRX-­P4-­003 is a novel, abuse-deterrent dopamine norepinephrine reuptake inhibitor incorporating an active isomer of fencamfamine (FCF). FCF is a Schedule IV stimulant that has been prescribed for decades in Europe and elsewhere overseas, primarily for depressive daytime fatigue, lack of concentration, and lethargy.

According to Praxis, PRX-­P4-­003 is specifically designed to produce therapeutic stimulant activity when delivered orally—but not if illicitly injected—since PRX-P4-003 is a substrate of pancreatic lipase, an enzyme whose activity is almost entirely restricted to the gut. That minimizes the potential for its oral abuse, the company reasons.

In a study presented at the 2017 Annual Meeting of the American College of Neuropsychopharmacology, held in Palm Springs, CA, and published in the journal Drug and Alcohol Dependence, orally-dosed PRX-P4-003 was shown to possess the established biological activity of stimulants, while pharmacokinetically limiting the potential for IV abuse in preclinical models. 

Praxis is initially developing PRX-P4-003 for the treatment of binge eating disorder. The company said it believes the prodrug could also treat apathy in Alzheimer’s disease patients, and plans to carry out a follow-on proof-of-concept study in that indication.

Alchem Laboratories will provide manufacturing services supporting Praxis’ ongoing development of PRX-P4-003.

“We believe that PRX-P4-003 may offer an innovative solution in providing patients the benefits of proven therapeutic stimulant activity with a significantly reduced risk of abuse,” Praxis CEO Sandeep Patil, Ph.D., M.D., said in a statement. “We are pleased to receive this highly competitive SBIR award as we work diligently to build upon our promising preclinical data.”

Praxis said PRX-P4-003 could address the unmet need for effective abuse-deterrent stimulant formulations since present-day stimulants are classified as Schedule II controlled drugs due to a significantly high risk of addiction.

The company cited a 2016 report by Persistence Market Research projecting that the stimulant market for ADHD alone will grow to $25 billion annually in 2024, based on a compound annual growth rate of 6.2%.

The SBIR Grant (R44MH116764) was awarded by the NIH’s National Institute of Mental Health.

Based in Menlo Park, CA, Praxis focuses on developing treatments for chronic neuropsychiatric and neurodegenerative disorders.

Previous articleReputed Oncogene May Act as a Tumor Suppressor
Next articleDNA/RNA Sequencing Offers Hope to Drug-Resistant Multiple Myeloma Patients